Related Experiment Video
Updated: Aug 17, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis
Enrico Franceschi1, Giovanna Cavallo, Luciano Scopece
1Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, 40139, Italy.
Abstract:
Herein we describe the case of a patient with primary diffuse leptomeningeal gliomatosis (PDLG). After surgery and ventriculoperitoneal shunt placement, due to poor general conditions, the patient was not eligible for radiotherapy. For this reason we decided to start a systemic chemotherapy treatment with Temozolomide (150 mg/m2 per day for 5 days every 4 weeks). After three cycles a partial response was achieved with a clear improvement of general conditions. In our knowledge, this is the first time that PDLG treatment with Temozolomide has been described.

